Cargando…

Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease

BACKGROUND: Coronary artery disease (CAD) patients are at risk for life-threatening ventricular arrhythmias (VA) related to scar tissue. Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) can accurately identify myocardial scar extent. It has been shown that scar extent, particu...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexandre, Joachim, Saloux, Eric, Dugué, Audrey Emmanuelle, Lebon, Alain, Lemaitre, Adrien, Roule, Vincent, Labombarda, Fabien, Provost, Nicole, Gomes, Sophie, Scanu, Patrice, Milliez, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610203/
https://www.ncbi.nlm.nih.gov/pubmed/23331500
http://dx.doi.org/10.1186/1532-429X-15-12
_version_ 1782264419673178112
author Alexandre, Joachim
Saloux, Eric
Dugué, Audrey Emmanuelle
Lebon, Alain
Lemaitre, Adrien
Roule, Vincent
Labombarda, Fabien
Provost, Nicole
Gomes, Sophie
Scanu, Patrice
Milliez, Paul
author_facet Alexandre, Joachim
Saloux, Eric
Dugué, Audrey Emmanuelle
Lebon, Alain
Lemaitre, Adrien
Roule, Vincent
Labombarda, Fabien
Provost, Nicole
Gomes, Sophie
Scanu, Patrice
Milliez, Paul
author_sort Alexandre, Joachim
collection PubMed
description BACKGROUND: Coronary artery disease (CAD) patients are at risk for life-threatening ventricular arrhythmias (VA) related to scar tissue. Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) can accurately identify myocardial scar extent. It has been shown that scar extent, particularly scar transmurality, percent scar and scar mass, are associated with the occurrence of appropriate implantable cardioverter-defibrillator (ICD) therapy. However, quantification of transmurality extent has never been studied. The purpose of our study was to evaluate whether different methods quantifying scar transmurality, percent scar and scar mass (assessed with LGE-CMR) can predict appropriate ICD therapy in CAD patients with a long term follow-up period. METHODS AND RESULTS: We enrolled retrospectively 66 patients with chronic CAD referred for primary or secondary preventive ICD implantation and LGE-CMR before ICD implantation. Using LGE-CMR, scar extent was assessed by measuring scar mass, percent scar and transmural scar extent using four different methods. The median follow-up duration was 41.5 months (interquartile range 22–52). The endpoint was the occurrence of appropriate device therapy and occurred in 14 patients. Pre-ICD revascularization and transmural scar extent were significantly associated with the study endpoint but the latter was especially highly dependent on the method used. Patients with appropriate device therapy had also larger scar mass (29.6 ± 14.5 g vs 17.1 ± 8.8 g, p = 0.004), and larger percent scar (15.1 ± 8.2% vs 9.9 ± 5.6%, p = 0.03) than patients without appropriate device therapy. In multivariate analysis, scar extent variables remained significantly associated with the study end-point. CONCLUSIONS: In this study of CAD patients implanted for primary or secondary preventive ICD, pre-ICD revascularization and scar extent studied by LGE-CMR were significantly associated with appropriate device therapy and can identify a subgroup of CAD patients with an increased risk of life-threatening VA. Depending of the method used, transmural scar extent may vary significantly and needs further studies to obtain a validated and consensual study method.
format Online
Article
Text
id pubmed-3610203
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36102032013-03-29 Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease Alexandre, Joachim Saloux, Eric Dugué, Audrey Emmanuelle Lebon, Alain Lemaitre, Adrien Roule, Vincent Labombarda, Fabien Provost, Nicole Gomes, Sophie Scanu, Patrice Milliez, Paul J Cardiovasc Magn Reson Research BACKGROUND: Coronary artery disease (CAD) patients are at risk for life-threatening ventricular arrhythmias (VA) related to scar tissue. Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) can accurately identify myocardial scar extent. It has been shown that scar extent, particularly scar transmurality, percent scar and scar mass, are associated with the occurrence of appropriate implantable cardioverter-defibrillator (ICD) therapy. However, quantification of transmurality extent has never been studied. The purpose of our study was to evaluate whether different methods quantifying scar transmurality, percent scar and scar mass (assessed with LGE-CMR) can predict appropriate ICD therapy in CAD patients with a long term follow-up period. METHODS AND RESULTS: We enrolled retrospectively 66 patients with chronic CAD referred for primary or secondary preventive ICD implantation and LGE-CMR before ICD implantation. Using LGE-CMR, scar extent was assessed by measuring scar mass, percent scar and transmural scar extent using four different methods. The median follow-up duration was 41.5 months (interquartile range 22–52). The endpoint was the occurrence of appropriate device therapy and occurred in 14 patients. Pre-ICD revascularization and transmural scar extent were significantly associated with the study endpoint but the latter was especially highly dependent on the method used. Patients with appropriate device therapy had also larger scar mass (29.6 ± 14.5 g vs 17.1 ± 8.8 g, p = 0.004), and larger percent scar (15.1 ± 8.2% vs 9.9 ± 5.6%, p = 0.03) than patients without appropriate device therapy. In multivariate analysis, scar extent variables remained significantly associated with the study end-point. CONCLUSIONS: In this study of CAD patients implanted for primary or secondary preventive ICD, pre-ICD revascularization and scar extent studied by LGE-CMR were significantly associated with appropriate device therapy and can identify a subgroup of CAD patients with an increased risk of life-threatening VA. Depending of the method used, transmural scar extent may vary significantly and needs further studies to obtain a validated and consensual study method. BioMed Central 2013-01-19 /pmc/articles/PMC3610203/ /pubmed/23331500 http://dx.doi.org/10.1186/1532-429X-15-12 Text en Copyright ©2013 Alexandre et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Alexandre, Joachim
Saloux, Eric
Dugué, Audrey Emmanuelle
Lebon, Alain
Lemaitre, Adrien
Roule, Vincent
Labombarda, Fabien
Provost, Nicole
Gomes, Sophie
Scanu, Patrice
Milliez, Paul
Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease
title Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease
title_full Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease
title_fullStr Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease
title_full_unstemmed Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease
title_short Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease
title_sort scar extent evaluated by late gadolinium enhancement cmr: a powerful predictor of long term appropriate icd therapy in patients with coronary artery disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610203/
https://www.ncbi.nlm.nih.gov/pubmed/23331500
http://dx.doi.org/10.1186/1532-429X-15-12
work_keys_str_mv AT alexandrejoachim scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT salouxeric scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT dugueaudreyemmanuelle scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT lebonalain scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT lemaitreadrien scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT roulevincent scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT labombardafabien scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT provostnicole scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT gomessophie scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT scanupatrice scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease
AT milliezpaul scarextentevaluatedbylategadoliniumenhancementcmrapowerfulpredictoroflongtermappropriateicdtherapyinpatientswithcoronaryarterydisease